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A B S T R A C T
Background: Atrial ﬁbrillation (AF) is the most common arrhythmia and is associated with increased
morbidity and mortality. Thus, identifying subjects with unknown AF or at higher risk for future AF in the
general population is of importance. B-type natriuretic peptide (BNP) is linked with silent cardiac
diseases. We evaluated the association of BNP with incident AF in a large population-based cohort study.
Methods: We included subjects from the population-based Heinz Nixdorf Recall study without known
coronary heart disease, prior stroke, history of open heart surgery, heart-device therapy, or prevalent AF
at baseline. Association of continuous and binary (31 pg/ml for male, 45 pg/ml for female) BNP with
incident AF after 5 years was assessed using logistic regression analysis.
Results: A total of 3067 subjects (mean age 58.9 years, 47.9% male) were included in this analysis.
Subjects with incident AF (n = 42) had higher levels of BNP (median (Q1; Q3): 33.2 pg/ml (19.4; 50.5) vs.
16.9 pg/ml (9.2; 30.2)). Likewise, BNP was associated with incidence of AF both in univariate model and
when adjusting for AF risk factors (odds ratio (OR) (95% conﬁdence interval (CI)): BNP as continuous
variable: 1.27 (1.09; 1.47), p = 0.002; BNP as binary variable: 2.68 (1.41; 5.11) with AF risk factor
adjustment). Notably, especially younger subjects (<60 years) showed stronger association with
incident AF than older ones (OR (95%CI) for dichotomized BNP: 7.20 (1.60; 32.49), p = 0.01 for <60 years,
vs. 2.13 (0.89; 5.09), p = 0.09 for 60–70 years, and 4.40 (1.29; 14.97), p = 0.02 for >70 years).
Conclusions: Elevated levels of BNP are associated with signiﬁcant excess of incident AF, independent of
traditional AF risk factors in the general population. Gender-speciﬁc BNP thresholds may help in
prevention by detecting unknown or future AF, which carries a high risk of stroke events.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Atrial ﬁbrillation (AF) – the most common arrhythmia – is a major
risk factor for stroke, which is one of the leading causes of death and
long-term disability [1]. The risk for AF increases with age andDOI of commentary article: http://dx.doi.org/10.1016/j.jjcc.2014.08.009
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being asymptomatic [2]. Besides age, hypertension, obesity, and
female sex are known risk factors for the development of AF [3].
Although the exact mechanisms leading to AF are not completely
understood, atrial remodeling is a hallmark in the genesis [4].
Structural heart diseases such as coronary artery disease, left
ventricular dysfunction, and valvular diseases contribute to atrial
remodeling and may trigger AF as well [5]. To improve the prognosis
and to avoid AF-associated events such as stroke, detection of AF at
early stages represents an important challenge.
B-type natriuretic peptide (BNP) is a cardiac hormone secreted
from myocytes in response to ventricular and atrial wall stress, and reserved.
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BNP is increased in subjects with early stages of cardiac diseases
such as diastolic dysfunction and left ventricular hypertrophy
which also are associated with AF [7,8]. In population-based
studies, BNP predicted major cardiovascular outcomes in subjects
without known cardiac diseases [9,10]. However, data on the
ability of BNP to predict future AF based on general population
cohorts are limited.
Recently, we determined gender-speciﬁc values for increased
BNP (31 pg/ml for men, 45 pg/ml for women), leading to relevant
improvement of risk prediction for coronary and cardiovascular
events compared to the general cutoff value of 100 pg/ml which is
widely accepted in clinical practice for the diagnosis of heart
failure in patients with dyspnea [11]. However, whether these
thresholds are associated with incident AF and qualify for
screening tests in the general population remains unclear.
Therefore, the aim of the present analysis was to investigate (1)
the association of BNP with incident AF, and moreover, (2) the
association between the predeﬁned thresholds and AF and to
assess whether a potential predictive value exists when added to
known AF risk factors.
Methods
Participants
The Heinz Nixdorf Recall study is a population-based,
prospective cohort study. The participants were randomly selected
from mandatory city registries from Bochum, Essen, and Mu¨lheim.
Details about recruitment and study design have been previously
published [12]. In brief, 4814 subjects (50.3% females) aged 45–75
years were recruited. All participants provided written informed
consent, and the study was approved by the institutional ethical
committee at the University Essen, Germany. Between 2000 and
2003 the baseline visit was performed and follow-up examinations
were conducted after 5 years.
Cardiovascular risk factors and covariate deﬁnitions
Traditional cardiovascular risk factors were measured at
baseline examination with details being previously reported
[13]. For blood pressure measurement, the mean of the second
and third measure was calculated. Hypertension was deﬁned as
systolic blood pressure >140 mmHg or diastolic blood pressure
>90 mmHg or intake of hypertensive medication. Body mass index
(BMI) was calculated as body weight divided by square of height.
Diabetes was deﬁned as a history of diabetes, being on medical
treatment for diabetes, or having blood glucose levels as previously
published, and smoking status was assessed by a computer-
assisted interview [13].
Electron-beam computed tomography
Electron-beam computed tomography (EBCT) scans were
performed with a C-100 and C-150 scanner (GE Imatron, South
San Francisco, CA, USA) without the use of contrast media.
Coronary artery calcium (CAC) was deﬁned as a focus of at least 4
contiguous pixels with a CT density >130 Hounsﬁeld units. CAC
was quantiﬁed using the Agatston method and computed by the
sum of all foci in the epicardial coronary system [14].
Measurement of BNP at baseline
Plasma samples obtained from EDTA blood were aliquoted and
stored at 80 8C until further use. We measured the physiologi-
cally active BNP molecule using the Siemens ADVIA Centaur BNPassay (Siemens, Erlangen, Germany). The analytic functional
sensitivity of the assay which represents the lowest BNP
concentration determined was 2 pg/ml.
Electrocardiogram recording and AF deﬁnition
Subjects’ electrocardiograms (ECGs) were performed at initial
enrollment and at follow-up examination after 5 years with details
being previously described [15]. ECGs were interpreted automati-
cally using the integrated 12SL-Code1 which has been validated
and used also by others [16]. ECG ﬁndings were coded and
transferred to our database. Prevalent AF was based on the ECG
ﬁndings at enrollment and at follow-up examination after 5 years,
respectively. As AF was no primary study endpoint, no validated
information of AF status between baseline and follow-up
examination are available. For this analysis we excluded subjects
with prevalent or prior diagnosis of AF at baseline and incident AF
was deﬁned as prevalent AF at follow-up examination.
Statistical analysis
Continuous variables are reported as mean  standard deviation
(SD) or median (25th, 75th percentile) and discrete variables are
given in frequency and percent. Distribution of cardiovascular risk
factors was assessed for the total cohort and stratiﬁed by incident AF
(Table 1). Differences between groups were evaluated with t-tests
and chi-square tests.
The association of BNP with incident AF was investigated using
logistic regression (LR) with adjustment sets as follows: (1)
unadjusted, (2) age and gender adjusted (model 1), (3) additional
for AF risk factors including BMI and hypertension (model 2), (4)
additional for CAC (model 3). Hypertension was deﬁned as stage 1
or 2 hypertension by JNC7 (The Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure) [17] or the intake of
hypertensive medication. Odds ratios (OR) were calculated per
each standard deviation of BNP (= 22.84 pg/ml) (gender-speciﬁc
analyses: 19.54 pg/ml for male, 24.86 pg/ml for female, respec-
tively) and for dichotomized BNP thresholds. We used the recently
published BNP threshold of 35 pg/ml [18] for heart-failure patients
with non-acute symptoms and the gender-speciﬁc BNP thresholds
(31 pg/ml for male and 45 pg/ml for female subjects) [11].
Hosmer–Lemeshow test was used to assess the goodness of ﬁt for
all models. As sensitivity analyses we excluded subjects who
underwent ablation therapy prior to baseline or between baseline
and follow-up.
Finally, C-statistics and receiver operating characteristics were
calculated to assess the value of BNP for discrimination of subjects
with and without incident AF in addition to AF risk factors. All
analyses were performed using SAS software (Version 9.2, SAS
Institute Inc., Cary, NC, USA), except for the boxplots which were
generated using R 2.15.0 (http://cran.r-project.org/). A p-value of
<0.05 indicated statistical signiﬁcance.
Results
Overall 3067 subjects (mean age 58.9  7.6 years, 47.9% males)
were included in the analysis with median (Q1; Q3) BNP levels of
17.1 pg/ml (9.2; 30.5). Median and interquartile range of plasma
natriuretic peptide values were higher in female compared to male
subjects (21 pg/ml (11.7; 35.6) vs. 13.3 pg/ml (7.1; 23.6) for women
and men, respectively).
From the initial cohort of 4814 subjects, 327 were excluded due
to coronary heart disease at baseline, and additionally 159 died and
407 were lost to follow-up. Of the 3921 subjects present at baseline
and follow-up examination, 79 of the remaining subjects had a
Table 1
Baseline characteristics for total cohort and stratiﬁed for incident AF.
Overall No AF AF at follow-up p-value
N 3067 3025 42
Age (years) 58.9  7.6 58.8  7.5 65.7  6.3 <0.0001
Male (%) 1470 (47.9) 1444 (47.7) 16 (38.1) 0.07
Body mass index (kg/m2) 27.6  4.3 27.6  4.3 31.3  5.8 <0.0001
Systolic blood pressure (mmHg) 132.1  20.5 131.9  20.5 140.1  19.3 0.01
Diastolic blood pressure (mmHg) 81.4  10.7 81.4  10.7 82.0  11.0 0.69
Hypertensive medication (%) 903 (29.4) 877 (29.0) 26 (61.9) <0.0001
Hypertension 1584 (51.7) 1551 (51.3) 33 (78.6) 0.0004
Total cholesterol mg/dl 230.9  38.6 231.2  38.6 214.8  33.6 0.006
LDL cholesterol, mg/dl 146.2  35.7 146.4  35.7 135.9  33.0 0.06
HDL cholesterol, mg/dl 59.4  17.3 59.4  17.3 57.7  33.0 0.52
Smoking
Current 689 (22.5) 685 (22.6) 4 (9.5)
Former 1032 (33.6) 1018 (33.7) 14 (33.3)
Never 1346 (43.9) 1322 (43.7) 24 (57.2) 0.09
Diabetes 332 (10.8) 329 (10.9) 3 (7.1) 0.44
BNP Median (q1;q3) 17.1 (9.2; 30.5) 16.9 (9.2; 30.2) 33.2 (19.4; 50.5) <0.0001
BNP 100 pg/ml 37 (1.2) 35 (1.2) 2 (4.8) 0.04
BNP 31 pg/ml for male and 45 pg/ml for female 490 (16.0) 471 (18.6) 19 (45.2) <0.0001
BNP 35 pg/ml 617 (20.1) 597 (19.7) 20 (47.6) <0.0001
AF, atrial ﬁbrillation; LDL, low-density lipoprotein; HDL, high-density lipoprotein; BNP, B-type natriuretic peptide.
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therapy (valve surgery, pacemaker, or deﬁbrillator). At baseline,
BNP measures were available for 3383 subjects of this cohort. A
total 76 subjects had no status of heart rhythm at baseline and 37
had prevalent AF at baseline, in addition, 5 had no AF status at
follow-up. One or more covariates were missing in 198 subjects.
Due to excluding subjects with prior cardiovascular diseases, these
subjects had also a higher cardiovascular risk variables proﬁle
compared to the analyzed cohort (e.g. excluded subjects had a
higher BMI, systolic blood pressure, and CAC and also more males
and diabetic subjects were excluded). As sensitivity analysis, we
excluded 13 subjects, which reported about ablation therapy prior
to baseline or during follow-up resulting in an analyzing cohort of
3054. Estimated ORs did not differ noticeably (data not shown).
The subject’s baseline characteristics stratiﬁed by incident AF
status are depicted in Table 1. Fig. 1 shows the distribution of BNP
levels in subjects with vs. without incident AF; subjects with
incident AF had higher BNP levels.Fig. 1. Boxplot of baseline B-type natriuretic peptide by incident atrial ﬁbrillation
status.Overall, subjects with incident AF had higher frequency of
cardiovascular risk factors (Table 1). This effect was also seen when
stratifying by BNP levels. Subjects with low BNP levels and incident
AF were older (mean age: 65.0 years vs. 58.2 years, p < 0.0001),
more obese (mean BMI: 31.4 vs. 27.5, p < 0.0001), and had
hypertension more frequently (69.6% vs. 48.4%, p = 0.04), but had
lower total (213.6 mg/dl vs. 231.8 mg/dl, p = 0.03) and low-density
lipoprotein cholesterol levels (131.3 mg/dl vs. 147.1 mg/dl,
p = 0.04) compared to those without incident AF and low BNP
levels. Subjects with high BNP levels, but without incident AF were
younger (mean age: 62.4 years vs. 66.6 years, p = 0.01) and less
obese (mean BMI: 28.2 vs. 31.2, p = 0.004) compared to those with
incident AF and high BNP levels. Also, women (98.0% vs. 94.2%,
p = 0.03) and subjects without hypertension (98.7% vs. 94.9%,
p = 0.04) were more prone to be in this ﬁrst group.
Association of BNP with new onset of AF
After 5.1  0.3 years of follow-up, 42 individuals experienced AF.
Incidence of AF was higher in subjects with BNP above the gender-
speciﬁc thresholds of 31 pg/ml for men and 45 pg/ml for women (3.9%
vs. 0.9%). Using these gender-speciﬁc thresholds more subjects at
higher risk for AF were identiﬁed compared to the established cut-off
of 100 pg/ml (45.2% vs. 4.8% of all subjects with incident AF). The
higher sensitivity of the gender-speciﬁc thresholds consequently
involves a lower speciﬁcity of 84.4% vs. 98.8% for the 100 pg/ml
threshold, which is used for the diagnosis of heart failure. LR analyses
for new onset of AF are shown in Table 2. In unadjusted model,
subjects with a BNP level above the gender-speciﬁc thresholds at
baseline had more than four-fold increased risk for AF within 5 years.
Associations were slightly attenuated but remained statistically
signiﬁcant after further adjustment for age, gender, and AF risk factor
(ancillary additional including BMI and hypertension) both in
models with BNP as continuous variable and as binary variable.
Adding CAC to the full model did not inﬂuence the association of BNP
and incident AF.
In additional analysis we compared the gender-speciﬁc thresh-
olds with the general, non-gender speciﬁc cut-off of 35 pg/ml
which led to a similar identiﬁcation of subjects with incident AF
(45.2% vs. 47.6% of all subjects with incident AF). Likewise,
association of the gender-speciﬁc analysis vs. the general threshold
of 35 pg/ml revealed comparable results [OR (95%CI): 4.48 (2.42;
8.29) vs. 3.70 (2.01; 6.82) for unadjusted model, 2.69 (1.41; 5.15)
Table 3
Logistic regression for the association of BNP with new-onset of AF stratiﬁed by age group (<60 years, 60–70 years, 70 years).
Model BNP as continuous variable
(per each standard deviation)
BNP 31 pg/ml for male and 45 pg/ml
for female
Age (years) N AF OR (95% CI) p-value OR (95% CI) p-value
<60 1587 7 2.12 (1.25; 3.61) 0.006 7.20 (1.60; 32.49) 0.01
60–70 1177 23 1.25 (1.05; 1.48) 0.01 2.13 (0.89; 5.09) 0.09
70 303 12 1.17 (0.80; 1.70) 0.42 4.40 (1.29; 14.97) 0.02
AF, atrial ﬁbrillation; BNP, B-type natriuretic peptide; OR, odds ratio.
Table 2
Logistic regression for the association of BNP with new onset atrial ﬁbrillation.
Model BNP as continuous variable
(per each standard deviation)
BNP as binary variable
(31 pg/ml for male and 45 pg/ml for female)
Odds ratio (95%-CI) p-value Odds ratio (95%-CI) p-value
Unadjusted 1.38 (1.17; 1.62) 0.0001 4.48 (2.42; 8.29) <0.0001
Model 1 (age and gender) 1.29 (1.11; 1.50) 0.001 2.86 (1.51; 5.40) 0.001
Model 2 (AF risk factorsa) 1.27 (1.09; 1.47) 0.002 2.68 (1.41; 5.12) 0.003
Model 3 (Model 2 + CAC) 1.29 (1.10; 1.50) 0.001 2.69 (1.41; 5.15) 0.003
AF, atrial ﬁbrillation; BNP, B-type natriuretic peptide; CAC, coronary artery calcium.
a AF risk factors: age, sex, body mass index, hypertension.
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gender-speciﬁc and gender matched threshold, respectively].
Analyzing the associations stratiﬁed by sex, results did not vary
considerably; we only observed a trend toward stronger associa-
tion for male compared to female subjects (OR (95%CI): 1.49 (1.23;
1.82) for males vs. 1.34 (1.09; 1.65) for females, respectively using
continuous BNP).
LR analyses for incident AF, stratiﬁed by three age groups are
shown in Table 3. In unadjusted models we report the strongest
association in the lowest age group. Subjects younger than 60 years
had more than seven-fold increased risk for incident AF using the
gender-speciﬁc thresholds. Association remained after additional-
ly adjusting for hypertension, however with only low number of
events per variable.
BNP for prediction of new onset of AF
Considering the traditional AF risk model (model 2) the
contribution of BNP resulted in an increase in the area under
the curve (AUC) for discrimination of subjects with and without
incident AF for the continuous BNP variable, however, not reaching
statistical signiﬁcance (AUC: 0.826 to 0.837, p = 0.06 for continu-
ous BNP variable). Using the gender-speciﬁc thresholds, the
improvement in the AUC was of comparable size but wider
conﬁdence limits (AUC: 0.826 to 0.837, p = 0.33 for dichotomized
BNP). Comparable results were shown using the cut-off of 35 pg/ml
(AUC: 0.826 to 0.838, p = 0.31).
Discussion
Within this population-based study, we examined in subjects
without known cardiovascular diseases, the association of BNP as
continuous and binary variable with predeﬁned gender-speciﬁc
BNP thresholds with new onset of AF as well as its value for risk
prediction above traditional AF risk factors. Increased BNP levels
were associated with excessive incidence of AF, e.g. resulting in a
four-fold risk in a 5-year period for subjects with a BNP level
31 pg/ml for men and 45 pg/ml for women, in the crude model.
The association remained statistically signiﬁcant after adjustment
for traditional AF risk factors and CAC. Notably, associations were
more pronounced in younger subjects. Taken together, our results
point toward an independent association of BNP as well as thepredeﬁned gender-speciﬁc BNP values for incident AF independent
of traditional AF risk factors.
BNP is commonly used for the diagnosis of heart failure [6];
however, there is growing evidence that also in a preclinical
setting, measurement of BNP may improve risk prediction in the
general population. It was suggested that BNP reﬂects early stages
of cardiac diseases. These suggestions were conﬁrmed in a study
showing that BNP screening in asymptomatic patients is able to
identify existing cardiac diseases [19].
BNP is mainly released from ventricular myocytes in response
to ventricular wall stress, but also from atrial myocytes. In patients
with paroxysmal and persistent AF the atrium is the major site of
BNP release [20] and therefore, elevated levels of natriuretic
peptides have been reported in patients with prevalent AF
compared to patients with sinus rhythm [21]. Moreover, popula-
tion-based studies have shown that a single measurement of
elevated BNP also predicts future AF [22]. A possible explanation
for the role of natriuretic peptides in the pathogenesis of AF is that
BNP levels are increased in cardiac diseases, such as left ventricular
hypertrophy, systolic and diastolic dysfunction, left atrial enlarge-
ment, and ischemia. Those are again linked to increased risk of
myocardial ﬁbrosis and remodeling, which is a hallmark in the
development of AF [23].
Unknown and untreated AF is the most common cardiac
disorder associated with embolic stroke [24]. Since patients are
often asymptomatic, diagnosis of AF is more difﬁcult. Identifying
subjects at higher risk for AF could help in the early diagnosis of AF
and thus, suitable treatment could avoid adverse events. Moreover,
an early diagnosis of AF with an early treatment could result in
stabilization of sinus rhythm.
Wang et al. ﬁrst reported from a large population-based cohort
that higher levels of natriuretic peptides are associated with risk of
future AF, independent of traditional risk factors [25]. Another and
to date the largest study by Patton et al. demonstrated an
association of NT-pro-BNP with incident AF, again independent of
traditional risk factors [22]. However, since the subjects of their
population-based cohort had a mean age over 72 years, it remains
unclear, if these results are applicable for younger subjects.
Moreover, the population did not represent healthy subjects,
including subjects with cardiovascular diseases such as previous
stroke, heart failure, and coronary artery disease at baseline.
Subjects in our population were younger and, therefore, more
K. Kara et al. / Journal of Cardiology 65 (2015) 453–458 457suitable for screening programs, and additionally free from
cardiovascular diseases, such as previous stroke. Nevertheless,
these studies clearly suggest that higher BNP levels are associated
with incident AF, but no study investigated potential thresholds for
an easy screening test for AF. In particular from the perspective of
preventive cardiology it would be more useful to have a gender-
speciﬁc BNP value with a sufﬁcient precision. To date, there is a
lack of studies investigating this context. In our recently published
work we determined the gender-speciﬁc 90th percentile of BNP in a
subgroup without determinants of increased BNP and demon-
strated an association of these BNP thresholds (31 pg/ml for males
and 45 pg/ml for females) with incident major cardiovascular and
coronary events [11]. Until now, it was unclear if these determined
thresholds are also applicable for AF risk prediction. This is the ﬁrst
study, investigating the predictive value of BNP thresholds,
determined from a large healthy cohort, for incident AF. Our
results show that subjects above these gender-speciﬁc determined
thresholds have more than a 2.5-fold risk for incident AF and that
the effect of BNP is not mediated by known traditional risk factors
for AF. In addition, comparing our gender-speciﬁc thresholds to the
recently published BNP threshold of 35 pg/ml for heart-failure
patients with non-acute symptoms, association with AF and
discrimination of subjects with and without AF were comparable.
However, since gender-speciﬁc differences in BNP levels are
known, we recommend using the proposed gender-speciﬁc
thresholds.
Implications
Identifying cardiac diseases in early stages remains a challenge
in modern medicine. BNP is the ﬁrst biomarker that may improve
cardiac risk prediction above traditional risk factors in the general
population and it seems to reﬂect pancardiac damage in early
stages and therefore may be a powerful prognostic marker for
cardiovascular outcome and mortality. It has to be acknowledged
that the assessment of a biomarker is feasible using a simple blood
test. Recently gender-speciﬁc thresholds (31 pg/ml for males,
45 pg/ml for females, respectively) for asymptomatic subjects have
been published, which identify subjects at higher risk for major
cardiovascular and coronary events. The present results show that
subjects with BNP levels above these thresholds are also at clearly
higher risk for AF. Interestingly, this association is notably stronger
in younger subjects (<60 years), which reﬂect clearly the target
group for screening programs.
Together with our previous ﬁndings, these data may help
clinicians and primary care practitioners to identify asymptomatic
subjects but with increased risk for future cardiovascular diseases
and events including AF via BNP who might be missed by current
risk stratiﬁcation algorithms. Also, the present ﬁndings may at
least in part explain an association of BNP with stroke. To detect AF,
determination of BNP could be established in screening programs
and thereby, also asymptomatic subjects with a higher BNP level
may qualify from a cardiological workup, e.g. performing 24-h
ECGs. The early diagnosis of AF with an initiating anticoagulation
therapy may prevent future strokes. However, this implication is
an issue for future investigations.
Strengths and limitations
The strengths of our study include its population-based sample
without known cardiovascular disease. Traditional cardiovascular
risk factors were measured using highly standardized protocols.
As a major limitation, only AF prevalent at the time of the
examinations was part of the study, missing subjects with sinus
rhythm at the time of the examination but with paroxysmal AF in
between. This results in a lower rate of incident AF compared toother studies, where AF is also examined between enrollment and
follow-up. However, despite the fact that AF was underestimated,
our results show a strong association of BNP with incident AF,
emphasizing the predictive value of BNP. Furthermore, due to the
lack of ECG examinations between initial enrollment and 5-year
follow-up, we were not able to assess time to AF incidence related
to initial BNP. Moreover, it may be acknowledged that the used
gender-speciﬁc thresholds were also determined in our study;
thus, the prediction of AF in the same cohort might be superior
compared to that in an independent cohort. For further analyses of
clinical relevance it is desirable to investigate the prognostic value
of these thresholds in other population-based cohorts.
Conclusion
Elevated levels of BNP are associated with signiﬁcant excess of
incident AF, independent of traditional AF risk factors and CAC in
the general population, notably with strongest association in
younger subjects. Thus, the gender-speciﬁc BNP threshold (31 pg/ml
for males and 45 pg/ml for females) may help in primary prevention
by detecting subjects with unknown or future AF, who thereby carry
a high risk for future stroke events.
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